Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study - The Lancet
Clinical and virological data of the first cases of COVID-19 in Europe: a case series - The Lancet Infectious Diseases
EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial - The Lancet
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study - The Lancet Haematology
Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial - The Lancet
The Lancet, 01 February 2020, Volume 395, Issue 10221, Pages 311-388, e16-e18
Poor clinical outcomes for patients with cancer during the COVID-19 pandemic - The Lancet Oncology
Rapid triage for COVID-19 using routine clinical data for patients attending hospital: development and prospective validation of an artificial intelligence screening test - The Lancet Digital Health
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases
Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis - The Lancet Oncology
Etrolizumab for ulcerative colitis: beyond what meets the eye - The Lancet Gastroenterology & Hepatology
Scabies outbreaks in ten care homes for elderly people: a prospective study of clinical features, epidemiology, and treatment outcomes - The Lancet Infectious Diseases
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial - The Lancet Regional Health – Americas
Changes in clinical trials of cancer drugs in mainland China over the decade 2009–18: a systematic review - The Lancet Oncology
A clinical prediction rule for ambulation outcomes after traumatic spinal cord injury: a longitudinal cohort study - The Lancet
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study - The Lancet Respiratory Medicine
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial - The Lancet Respiratory Medicine
Graphical abstracts
Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet Respiratory Medicine
The Lancet, 21 February 2015, Volume 385, Issue 9969, Pages 663-744
Lancet eBooks
Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial - The Lancet
Alzheimer's disease: clinical trials and drug development - The Lancet Neurology
The Lancet - YouTube
